Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch :
Am J Nurs. 2021 Nov 1;121(11):22. doi: 10.1097/01.NAJ.0000798988.85940.04.
The emergency use authorization for REGEN-COV (a combination of two monoclonal antibodies, casirivimab and imdevimab) has been revised to include postexposure prophylaxis of COVID-19 in adults and children 12 years of age and older who, if they become COVID-19 positive, are at high risk for severe disease.Prophylaxis with REGEN-COV is not a substitute for vaccination against COVID-19.
REGEN-COV（两种单克隆抗体 casirivimab 和 imdevimab 的组合）的紧急使用授权已修订，将其纳入用于 COVID-19 的暴露后预防，适用人群为成年人和 12 岁及以上儿童，如果他们 COVID-19 检测呈阳性，则有发生重症疾病的高风险。使用 REGEN-COV 进行预防并非 COVID-19 疫苗接种的替代品。
